Search
Search Results
##search.searchResults.foundPlural##
-
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4033PDF: 1070HTML: 3607Untitled: 180Cneo. Fig.1: 117Untitled: 109Untitled: 136Untitled: 137 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2212PDF: 1739HTML: 386 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3421PDF: 2296HTML: 23375Untitled: 214Untitled: 227Untitled: 242 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1425HTML: 484PDF: 845 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2221PDF: 1631HTML: 321 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1286PDF: 1087HTML: 219 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4479PDF: 1659HTML: 4082Tables and Images: 246 -
-
-
SOLITARY PLASMACYTOMA
3982PDF: 2227HTML: 1252fIGURES 1,2: 234 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1291PDF: 1035HTML: 234 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2610PDF: 1029HTML: 179Suppl. Files: 525 -
FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
3359PDF: 1268HTML: 2216 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9207PDF: 6135HTML: 87985Fig.1b: 196Fig.1c: 204Fig.2a: 190Fig.2b: 190Fig.4: 206Fig.2c: 194Fig.3: 194Tab.1: 246Tab.2: 220Tab.3: 204Tab.4: 240Fig1a: 199 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3627PDF: 2549HTML: 1525 -
-
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1610PDF: 1059HTML: 263 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7741PDF: 2455HTML: 1745Table 1.: 226Table 2.: 239Table 3.: 221Table 4.: 215 -
ASSOCIATION BETWEEN PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE INFECTION PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE
199PDF: 297Suppl. Files: 52HTML: 61 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1516PDF: 801Suppl. Files: 337Html: 141 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2863PDF: 1034HTML: 5531 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3431PDF: 1308HTML: 2234Fi.1 Gritti.Rambaldi: 216 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12563PDF: 1699HTML: 4232Cover letter: 209Figure 1: 216 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2219PDF: 999HTML: 2176 -
DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.
4873PDF: 1856HTML: 2170 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2161PDF: 1337HTML: 3508 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4096Suppl. Files: 1176PDF: 1099Html: 192 -
Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
1119PDF: 875HTML: 255 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1085PDF: 1195Suppl. Files: 574HTML: 94 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4418PDF: 1784HTML: 1112 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2947PDF: 1388HTML: 3583Untitled: 202Untitled: 215Untitled: 190 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1820PDF: 1187HTML: 258 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
2081PDF: 784HTML: 3119







